<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Bortezomib; Multiple myeloma; Proteasome inhibitors" /><meta name="IX" content="Bortezomib; Multiple myeloma; Proteasome inhibitors" /><title>Bortezomib: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP5441-bortezomib.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP5441-bortezomib.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP5441-bortezomib.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 07 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP5179-malignant-disease-and-immunosuppression.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="PHP5180-cytotoxic-drugs.htm">8.1 Cytotoxic drugs</a> &gt; <a href="PHP5425-other-antineoplastic-drugs.htm">8.1.5 Other antineoplastic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP5439-bexarotene.htm" title="Previous: BEXAROTENE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP5444-bortezomib.htm" title="Next: BORTEZOMIB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a303026.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bortezomib</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/21105-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Bortezomib</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: B &gt; Interactions of Bortezomib</p></div></li></ul><ul><li><h3>British National Formulary (4)</h3></li><li><a href="PHP5444-bortezomib.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">BORTEZOMIB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Bortezomib</p></div></li><li><a href="PHP5445-velcade.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Velcade®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.1 Cytotoxic drugs &gt; 8.1.5 Other antineoplastic drugs &gt; Bortezomib &gt; BORTEZOMIB</p></div></li><li><a href="PHP5668-introna.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">IntronA®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.4 Other immunomodulating drugs &gt; Interferon alfa &gt; INTERFERON ALFA</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22bortezomib%22%22multiple+myeloma%22%22proteasome+inhibitors%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (4)</a></li></ul><ul><li><h3>BNF for Children</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/PHP13913-drugs-used-in-hypoplastic-haemolytic-and-renal-anaemias.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders</p></div></li></ul><ul><li><h3>Handbook on Injectable Drugs</h3></li><li><a href="http://www.medicinescomplete.com/mc/hid/2010/a508004.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bortezomib</a><div class="breadcrumb"><p><strong>Handbook on Injectable Drugs</strong> &gt; Monographs &gt; B</p></div></li></ul><ul><li><h3>Stability-Indicating HPLC Methods for Drug Analysis</h3></li><li><a href="http://www.medicinescomplete.com/mc/hplc/2008/ch0002s0139.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bortezomib</a><div class="breadcrumb"><p><strong>Stability-Indicating HPLC Methods for Drug Analysis</strong> &gt; Monographs &gt; B</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/1800-a4-395-y.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Lymphomas</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Choice of Antineoplastic &gt; Management of malignant disease</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/21105-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bortezomib</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/01351.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bortezomib</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; B &gt; BO</p></div></li></ul><ul><li><h3>Remington: The Science and Practice of Pharmacy</h3></li><li><a href="http://www.medicinescomplete.com/mc/rem/2012/mono-B46.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Bortezomib</a><div class="breadcrumb"><p><strong>Remington: The Science and Practice of Pharmacy</strong> &gt; Part 3: Pharmaceutical and Medicinal Agents &gt; B</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E10E3E0R0D1713.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Bortezomib</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; B</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1>Bortezomib</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Bortezomib</strong>, a proteasome inhibitor, is licensed as monotherapy for the treatment of multiple myeloma that has progressed despite the use of at least one therapy, and where the patient has already had, or is unable to have, bone-marrow transplantation. It is also licensed for use in combination with melphalan and prednisolone for the treatment of previously untreated multiple myeloma in patients who are not eligible for high-dose chemotherapy with bone marrow transplantation. Bortezomib is given by intravenous injection.</p><div class="cI"><h3 class="cT">Important</h3>  <p>Bortezomib injection is for <strong>intravenous administration</strong> only. Inadvertent intrathecal administration with fatal outcome has been reported.</p> </div><div id="PHP5442" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bortezomib monotherapy for relapsed multiple myeloma (October 2007)</h3><p>Bortezomib monotherapy is an option for the treatment of progressive multiple myeloma in patients who are at first relapse having received one prior therapy and who have undergone, or are unsuitable for, bone-marrow transplantation, under the following circumstances:</p><ul><li><p>the response to bortezomib is measured using serum M protein after a maximum of four cycles of treatment, and treatment is continued only in patients who have a reduction in serum M protein of 50% or more (where serum M protein is not measurable, an appropriate alternative biochemical measure of response should be used) <strong>and </strong></p> </li><li><p>the manufacturer rebates the full cost of bortezomib if there is an inadequate response (as defined above) after four cycles of treatment.</p> </li></ul></div><div id="PHP5443" class="cI"><p class="cAE">NICE guidance</p><h3 class="cT">Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011)</h3><p>Bortezomib in combination with an alkylating drug and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma if:</p><ul><li><p>high-dose chemotherapy with stem cell transplantation is considered inappropriate <strong>and</strong></p> </li><li><p>the person is unable to tolerate or has contra-indications to thalidomide.</p> </li></ul><p>For thalidomide see <a title="BNF:target-block: NICE bortezomib and thalidomide 2" href="PHP5709-lenalidomide-and-thalidomide.htm#PHP5711">under Lenalidomide and thalidomide</a></p></div></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_PHP5444-bortezomib"><a href="PHP5444-bortezomib.htm" title="BORTEZOMIB">BORTEZOMIB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP5439-bexarotene.htm">Previous: BEXAROTENE</a> | <a class="top" href="PHP5441-bortezomib.htm#">Top</a> | <a accesskey="]" href="PHP5444-bortezomib.htm">Next: BORTEZOMIB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>